Glizide

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Glizide

Glizide is a prescription-only oral medication primarily used for managing blood glucose levels, featuring the active ingredient known by its nonproprietary name, Glipizide. It is a synthetic small molecule belonging to the Second-generation sulfonylurea class, which is a type of oral anti-diabetic drug.

Property Description
Active ingredient Glipizide
Form Tablets (Immediate-release & Extended-release)
Pharmacological class Sulfonylurea (Insulin Secretagogue)
General use Supporting glycemic control
Origin Synthetic

Glipizide's Class and Mechanism

Glipizide functions as an insulin secretagogue, meaning its core mechanism is to stimulate the pancreas to actively release its stored insulin. This action helps the body reduce circulating high blood sugar levels.

Glipizide is an oral hypoglycemic agent used to improve blood sugar control in adults with type 2 diabetes. The drug's relatively short plasma half-life is a differentiating factor within the sulfonylurea class, and it is typically positioned for adults needing active insulin release support to maintain consistent glucose regulation.


Dosage Forms and General Purpose

The active compound is available for oral administration in two primary pharmaceutical preparations: the immediate-release tablet (IR) and the extended-release tablet (ER). Both forms contain the same active ingredient, but the extended-release tablet is engineered to release the Glipizide steadily over a longer duration.

The sulfonylurea class of drugs promotes insulin secretion from the pancreatic beta cells, supporting their therapeutic utility in managing long-term glucose balance. This indicates that the drug's primary benefit comes from directly ensuring the pancreas releases the insulin necessary to manage sugar in the bloodstream, aiding in the maintenance of necessary glycemic control.

Regulatory References

  1. Glipizide - StatPearls - NCBI Bookshelf
  2. Sulfonylureas - StatPearls - NCBI Bookshelf

What side effects are possible with Glizide?

Possible Side Effects and Safety Information

The safety profile of Glizide (Glipizide), consistent with its classification as an insulin secretagogue, is primarily characterized by the risk of hypoglycemia (low blood sugar), which is the most frequent adverse reaction documented in regulatory sources.


Frequency-Classified Adverse Reactions

Adverse reactions are classified by official regulatory bodies based on documented incidence rates:

  • Common: Includes Hypoglycemia, which may be severe, along with common reactions affecting the Gastrointestinal Disorders (e.g., nausea, diarrhea) and Nervous System Disorders (e.g., headache, dizziness) as listed in the FDA and EMA documentation.
  • Rare: Includes serious hematologic effects such as Agranulocytosis (a severe reduction in white blood cells) and Thrombocytopenia, as well as Cholestatic Jaundice (a form of liver injury).

Serious Adverse Reactions and Safety Constraints

The regulatory label highlights rare but clinically significant risks. Severe hypoglycemia is a critical, label-documented risk. Other rare, serious risks include the hematologic and hepatobiliary issues mentioned. Additionally, the drug is contraindicated in patients with known hypersensitivity to Glipizide or other sulfonamide medications.

Safety constraints apply to specific patient groups. Older adults and individuals with renal or hepatic impairment are documented as being particularly susceptible to the effects of Glizide, leading to an increased risk of prolonged and severe hypoglycemia.


Time-Related and Cardiovascular Notes

Regulatory documents note that the risk of low blood sugar is typically highest at treatment initiation and during periods of dose adjustment. Furthermore, the label includes a special warning concerning an increased risk of cardiovascular mortality observed with another drug in the sulfonylurea class.

Overdose and Emergency Response

The regulatory documentation for Glizide overdose establishes hypoglycemia as the primary and most significant manifestation. Overdosage results in an excessive lowering of blood glucose, which can lead to mild symptoms such as diaphoresis and tachycardia, or rapidly escalate to severe hypoglycemic reactions. These severe reactions, which are explicitly recognized as medical emergencies, may present with seizure, convulsions, coma, or other forms of neurological impairment directly resulting from glucose deprivation. Official labeling states that severe hypoglycemia carries the risk of temporary or permanent impairment of brain function or death.

In the event of suspected overdose or the onset of severe symptoms, immediate medical attention and hospitalization are explicitly required by regulatory bodies. Treatment focuses on correcting the metabolic state with the administration of glucose, often followed by a continuous glucose infusion, as no specific drug antidote is known. Furthermore, due to the drug’s prolonged action, patients must be closely monitored for a minimum of 24 to 48 hours following apparent recovery due to the documented risk of hypoglycemia recurrence. Regulatory documents note that older people and those with liver disease are cited as having an increased risk for prolonged or more serious complications.

Therapeutic Uses of Glizide

What Glizide Treats: Main Uses and Benefits

Supporting Long-Term Glucose Balance in Type 2 Diabetes

Glizide is commonly used to manage Type 2 diabetes mellitus, a chronic condition marked by persistently high blood sugar (hyperglycemia). It is applied when glucose control is not achieved through diet and exercise alone, providing a foundation for sustained glycemic control that may play a role in mitigating the risk of long-term complications. Glizide is relevant for easing symptoms associated with systemic glucose imbalance.

It is often used in conditions presenting with significant symptomatic burden, including non-insulin-dependent diabetes. Glizide is relevant when supportive symptom management is appropriate and may assist with easing the symptom burden and maintaining functional stability.

“By assisting with lowering glucose, Glizide contributes to improved comfort during periods of heightened symptoms.”


Easing Hyperglycemic Symptom Burdens and Fatigue

The medication generally offers support in managing the uncomfortable symptom cluster driven by high sugar levels. This is relevant for easing manifestations like excessive thirst (polydipsia) and frequent urination (polyuria). Additionally, Glizide is relevant for managing chronic metabolic lassitude and fatigue. As blood sugar control improves, the medication may assist with supporting the body's energy levels.

Quick Fact: Relief for Polydipsia
Glizide may assist in easing the overall symptom load related to excessive thirst, a common sign of systemic glucose imbalance.

Eligibility and Restrictions for Use

Who Can and Cannot Use Glizide?

Glizide (Glipizide) is officially approved for use only by adults with Type 2 diabetes mellitus to support glycemic control.

Absolute Contraindications

Use is strictly contraindicated (must not be used) in patients with:

  • Type 1 Diabetes Mellitus
  • Diabetic Ketoacidosis (DKA)
  • Known hypersensitivity to the drug or any excipients.

Restricted Use and Special Populations

Official regulatory labeling defines specific conditions requiring caution or restriction:

  • Organ Impairment: Patients with hepatic impairment or renal impairment must use the medicine with caution, as these conditions carry an increased risk of severe, prolonged hypoglycemia.
  • Age Limitations: Safety and efficacy have not been established for the pediatric population (under 18 years). Older adults (age 65 and above) are advised to use the drug with caution.
  • Pregnancy and Lactation: Use is conditional. Documentation recommends discontinuing the medicine at least one month before expected delivery.
  • Gastrointestinal Narrowing: The extended-release formulation is officially advised to be avoided in cases of severe gastrointestinal narrowing.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Glizide (Glipizide) has officially documented interaction patterns categorized by their effect on blood glucose levels and drug exposure, as stated in regulatory prescribing information. Pharmacodynamic interactions can potentiate the glucose-lowering action, which increases the risk of hypoglycemia. Medicines that exhibit this additive effect include Nonsteroidal Anti-inflammatory Agents (NSAIDs), salicylates, and MAOIs. Beta-adrenergic Blocking Agents also potentiate this effect and may additionally mask the symptoms of low blood sugar. Conversely, certain classes, such as Corticosteroids and Thiazide Diuretics, are documented to reduce Glizide's effectiveness, potentially resulting in the loss of glycemic control.

Pharmacokinetic interactions alter the concentration of Glizide in the plasma. Fluconazole significantly increases Glizide's total exposure and plasma concentrations. To mitigate exposure reduction, Glizide extended-release tablets must be administered at least 4 hours prior to Colesevelam. The combination with Oral Miconazole is formally restricted or contraindicated by some regulatory authorities due to the documented potential for severe hypoglycemia. Furthermore, Alcohol (Ethanol) consumption is noted to cause severe low blood sugar. Specific patient conditions, such as G6PD deficiency or impaired hepatic function, are documented to heighten the risk of severe interaction outcomes.

Mechanism of Action

Glizide's primary mechanism involves direct interaction with the SUR1 subunit of the ATP-sensitive potassium ( K ATP) channel on pancreatic beta-cells. By closing this channel (inhibition), the drug triggers a cascade of cellular events, including depolarization and subsequent calcium influx . This action stimulates the exocytosis of stored insulin into the circulation, a process that occurs independent of the current blood glucose level.

The resulting influx of calcium ions ( Ca^2+) acts as the final and critical signal, increasing the activity within the cell's secretory pathway. This modulates the Ca^2+-dependent process responsible for fusing insulin vesicles with the cell membrane. This results in the core physiological effect of Glizide: a rapid increase in endogenous insulin concentration and the subsequent reduction in circulating blood glucose levels.

Beyond the pancreas, Glizide's mechanism involves secondary, extrapancreatic modulation of glucose homeostasis. This activity affects peripheral tissues, resulting in enhanced insulin receptor signaling and increased uptake and utilization of glucose by muscle and fat cells. This mechanism also contributes to the suppression of hepatic glucose output.

Dosage and Administration Information

How to Use Glizide

Glizide (Glipizide) is an oral medication used for long-term glycemic management, administered exclusively via the mouth. The drug is available in two primary pharmaceutical preparations: an Immediate-Release (IR) tablet and an Extended-Release (ER) tablet. The choice of form dictates the specific daily frequency and required timing in relation to food intake.


Dosing and Administration Schedule

Administration is initiated with a low starting dose which is subsequently adjusted based on the individual's blood glucose response. The maximum dose is explicitly defined by the formulation, constraining the total daily intake.

Form Starting Dose (Adult) Maximum Daily Dose Timing Relative to Meals
Immediate-Release (IR) Typically 5 mg once daily 40 mg Administered 30 minutes before a meal
Extended-Release (ER) Typically 5 mg once daily 20 mg Administered with breakfast or the first main meal of the day

Key Procedural Instructions

Dose Titration: Dose adjustments are executed gradually, following the initial start, with the extended-release form typically adjusted at approximate seven-day intervals to assess efficacy and response.

Special Handling: The extended-release tablet must be swallowed whole and must not be crushed, chewed, or divided, as this physical constraint is necessary to maintain the integrity of its controlled drug delivery system. For older adults and patients with hepatic impairment, a lower initial dose (e.g., 2.5 mg for ER) is utilized to accommodate altered drug clearance and reduce the potential for over-exposure. If a dose is missed, individuals should not take two doses at the same time to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Glizide

Evidence for Use in Type 2 Diabetes Management

The clinical evidence base for Glizide was established using Randomized Controlled Trials (RCTs). These studies primarily compared Glizide against placebos or other active medications. Researchers explored whether Glizide was associated with changes in specific blood tests known as glycemic biomarkers, specifically Glycated Hemoglobin ( HbA1c) and Fasting Plasma Glucose (FPG). Findings describe group patterns observed in adults with Type 2 Diabetes where researchers monitored changes in these markers.

Studies Examining Glizide When Used with Metformin

Glizide was also evaluated in clinical settings where study populations were already taking Metformin but required further support. These comparative trials explored whether adding Glizide was associated with additional changes in HbA1c and FPG measurements. The data show patterns related to further changes in these blood sugar markers when Glizide was evaluated as an add-on therapy.

Long-Term Research and Durability of Study Findings

When researchers look at the long-term evidence, they focus on durability—how well the observed changes are maintained. While research describes that study populations may maintain the observed changes in blood sugar measurements over a year, certainty remains low for periods exceeding two years. The results apply only to the populations studied, and long-term maintenance of these glycemic changes may vary between individuals.

Evidence in Specific Patient Groups

Most core evidence was observed in adults with Type 2 Diabetes, including specific research for the elderly patient population (age 65 and above). However, data for certain groups remain insufficient. For instance, Glizide was not evaluated in children, and evidence is limited for patients with severe liver or kidney conditions.

Research Gaps and What Remains Uncertain

The existing research primarily focuses on surrogate outcomes (blood markers), and the relevance of these biomarker changes to direct, long-term clinical events (like major cardiovascular events) is not fully established by dedicated Glizide trials. Furthermore, subgroup findings are uncertain for those with complex health challenges because comparative evidence is lacking or sample sizes were modest in the available studies.

Key Studies & References NICE Guideline NG28: Type 2 diabetes in adults: management

Frequently Asked Questions (FAQ)

Common questions about Glizide (FAQ)


Q: Is Glizide the same as [Brand Name]?

Glizide is the nonproprietary name for the active ingredient, Glipizide. It is the main component found in certain brand-name tablets, such as Glucotrol and Glucotrol XL. The active ingredient remains the same in both the generic and brand-name versions.

Q: Can Glizide cause weight gain or weight loss?

Official reports indicate that changes in weight have been noted during the use of Glizide. These changes can include both weight gain and, less commonly, weight loss. Patients who have concerns about potential changes to their weight can find detailed information in the product label.

Q: Does Glizide interact with common pain relievers like ibuprofen?

Yes, regulatory documents mention potential interactions with a class of pain relievers called Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes ibuprofen. Taking these together can intensify the glucose-lowering effect of Glizide. This indicates a potential for a heightened risk of experiencing low blood sugar, or hypoglycemia.

Q: How long does it typically take for Glizide to start working?

The drug's official pharmacokinetic data indicate that Glizide has a relatively rapid absorption and onset of action compared to some other medicines in its class. Once absorbed, it has a short plasma half-life, which refers to the time it takes for half of the active substance to be cleared from the bloodstream. It is important to follow the specified instructions regarding the timing of the dose relative to meals.

Q: What happens if I forget to take Glizide?

If you miss a dose, official patient information advises against taking two doses at the same time to compensate. You should take the missed dose as soon as you remember. However, if it is almost time for your next dose, the official information advises skipping the missed dose and continuing with the regular schedule.

Q: Does Glizide have a generic version available?

Yes, Glizide (, Glipizide) is the name of the generic active ingredient. It is available as a generic drug, which contains the exact same active ingredient as the brand-name products.

Q: Can Glizide cause dizziness or lightheadedness?

Official adverse reaction reports list dizziness as a common side effect. Lightheadedness may be associated with symptoms of low blood sugar (, hypoglycemia), which is the most frequent adverse reaction associated with this medication.

Q: Can Glizide be used by children?

The official product information specifies that Glizide is approved for use only by adults with Type 2 diabetes. The safety and effectiveness of this medication have not been established for the pediatric population, which includes anyone under the age of 18.

Q: Can Glizide make a pre-existing heart condition worse?

The drug's official label contains a special warning regarding an increased risk of cardiovascular mortality (death due to heart-related issues). This warning was observed with another drug in the same class (, sulfonylureas). This is why caution is generally applied when this class of medication is used.

Q: Are there any specific laboratory tests required before starting Glizide?

While the regulatory label does not mandate specific screening tests, the drug's use is often associated with the need for regular clinical and laboratory evaluations. These are necessary to determine the appropriate management strategy and to monitor the drug's ongoing effect.

Q: Is Glizide widely accepted internationally?

Yes, the active ingredient Glipizide is widely recognized internationally. It is classified by the World Health Organization (WHO) and is approved for medical use in the United States and various other jurisdictions globally.

Q: Does Glizide have any impact on mood or mental health?

Official reports include central nervous system effects as adverse reactions. These may include feelings of nervousness, anxiety, tremor, and drowsiness. In rare instances, depression or agitation have also been reported.

Q: Is there a maximum amount of time someone can take Glizide?

Official information does not define a maximum time limit for using Glizide. The continuance of the medication is determined by regular clinical and laboratory evaluations which check if the drug continues to be helpful for managing blood sugar levels.

Q: Can taking Glizide cause skin sensitivity to the sun?

Yes, photosensitivity has been reported, meaning the skin may become more sensitive to sunlight while using Glizide. If this occurs, measures to protect the skin from sun exposure are generally advised.

Q: Is Glizide effective for everyone with the condition?

Studies and official information indicate that the drug may be effective for some patients, including those who have not responded adequately to other drugs in the sulfonylurea class. However, official documents do not state that the drug is guaranteed to be effective for every individual with the condition.

Q: Will Glizide cure my condition, or just manage it?

Glizide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes. It is described as a long-term management tool to help control blood sugar levels, and is not generally regarded as a cure for the underlying condition.

How should Glizide be stored and disposed of?

How to Store and Dispose of Glipizide

Glipizide (Glizide) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with allowed excursions up to 30 C.


Storage Requirements

Detail Requirement
Temperature Store at controlled room temperature, away from excess heat.
Protection Keep the container tightly closed and store away from moisture.
Safety Keep this medicine out of the reach and sight of children.

Disposal Instructions

Expired or unused Glipizide must be disposed of safely. The preferred method is using a drug take-back program if one is locally available. If not, follow official household disposal guidelines, which involve mixing the tablets with an undesirable substance (like dirt or used coffee grounds) and sealing them in a bag before placing them in the trash. Do not flush the tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Glizide found in:

A-Z Index: